A Study Of Celecoxib Versus Diclofenac In Patients With Ankylosing Spondylitis

Ankylosing Spondylitis Clinical Trial

Official title:

A Twelve Week, Randomized, Double Blind Parallel Group Study Of Two Doses Of Celecoxib Compared To Diclofenac In Patients With Ankylosing Spondylitis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02528201
• Other study ID #: COXA-0508-247
• Secondary ID: A3191099
• Status: Completed
• Phase: Phase 4
• First received: June 18, 2015
• Last updated: August 18, 2015
• Start date: September 2002
• Est. completion date: November 2004

Study information

• Verified date: August 2015
• Source: Pfizer
• Contact: n/a
• Is FDA regulated: No
• Health authority: Norway: Regional Ethics Committee
• Study type: Interventional

Clinical Trial Summary

A clinical trial to assess the effect of celecoxib 200 milligrams (mg) once daily and 400 milligrams (mg) once daily compared to diclofenac three times daily in the treatment of Ankylosing Spondylitis (AS) for 12 weeks. This will be used to confirm the results of a prior 6 week trial.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 330
• Est. completion date: November 2004
• Est. primary completion date: November 2004
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Male or female, 18 to 75 years of age, inclusive.

• Clinical diagnosis of ankylosing spondylitis:

• Willing to stop existing NSAID/COX-2 inhibitor treatment for up to two weeks.

• Having given written informed consent to participate in the trial.

• Pain intensity = 40 mm on the visual analog scale, worsening by at least 30 % compared to that recorded at the screening visit.

• Last administration of analgesic without anti-inflammatory activity is = 8 h, the last administration of long-acting NSAIDs is = 72 h

Exclusion Criteria:

• Patients with acute peripheral articular disease (defined by the onset within 4 weeks prior to visit

• Known inflammatory enteropathy (e.g. ulcerative colitis, Crohn's disease).

• Ongoing extra-articular signs (e.g. cardiac involvement).

• Current painful vertebral compression.

• Requirement to start physiotherapy, re-education or manipulation

• History of clinical gastroduodenal ulcer in the year preceding inclusion, confirmed by endoscopy; continuing gastro-intestinal bleeding.

• Cardiac failure or known renal insufficiency that could be affected by study medication, chronic or acute hepatic insufficiency, significant coagulation disorders or history of asthma.

• Current or history of malignancy (except: patients having a basal cell carcinoma or other malignancy operated on and in remission for 5 years before inclusion in the trial).

• Pregnancy, women of childbearing potential not using adequate contraceptive methods or nursing mothers.

• Subject who has evidence of alcohol or drug abuse.

• Participation in any other clinical study within 30 days prior to the screening visit.

• Any condition that would prevent the patient from entering the study, according to the investigator's judgment.

• Known hypersensitivity to celecoxib, sulphonamides or any NSAID (including salicylic acid).

• Taking the following medications: Muscle relaxants, hypnotic, anxiolytics, sedatives, tranquillizers or antidepressants (unless stable for 2 weeks before screening and continuing throughout the trial), NSAIDs or COX-2 inhibitors other than study medication, acetylsalicylic acid (ASA) > 160 mg /day, anti-coagulants, ticlopidine, lithium, anti-TNF agents or methotrexate > 15 mg/week (Note: ASA = 160 mg/day for cardioprotection is permitted), Use of oral or systemic analgesic medication, except from paracetamol, within 3 days of study entry and through the study, Corticosteroids (PO/IM/IV/IA) in the 6 weeks preceding inclusion in the trial, Anti-ulcer medication including chronic (daily or almost daily) use of antacids [Note: Occasional use of antacids during the study will be permitted.]

• Change in dose of a slow-acting drug (e.g. sulfasalazin, methotrexate) in the past 60 days preceding inclusion in the trial.

• Taking paracetamol > 2000 mg/day (including during the screening period).

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Ankylosing Spondylitis
• Spondylitis
• Spondylitis, Ankylosing

Intervention

Drug:
• Celecoxib 200 milligrams
Celecoxib 200 milligrams once a day
• Celecoxib 400 milligrams
Celecoxib 400 milligrams once a day
• diclofenac 50 milligrams
diclofenac 50 milligrams three times a day

Locations

Country	Name	City	State
Norway	Ålesund sykehus	Ålesund
Norway	Martina Hansens hospital	Bærum Postterminal
Norway	Bekkestua legesenter	Bekkestua
Norway	Dr. Johannessen Kontor	Bergen
Norway	Dr.Wiigs kontor	Bergen
Norway	Nordland Medisinske Senter	Bodø
Norway	Sykehuset Buskerud HF	Drammen
Norway	Lægene på Kongens torv	Gamle Fredrikstad
Norway	Centre For Clinical Trials	Hamar
Norway	Harstad sykehus	Harstad
Norway	Haugesund sanitetsforenings revmatismesykehus	Haugesund
Norway	Horten legesenter	Horten
Norway	Solli Klinikk AS	Jessheim
Norway	Kongsvinger sykehus HF	Kongsvinger
Norway	Dr. Svensens kontor	Kristiansand
Norway	Vest-Agder sentralsykehus	Kristiansand
Norway	Lensbygda Legekontor	Lena
Norway	Helse Nord-Trøndelag HF, Sykehuset Levanger	Levanger
Norway	LSF Reumatismesykehus	Lillehammer
Norway	Helgelandssykehuset HF	Mo I Rana
Norway	Diakonhjemmet Hospital	Oslo
Norway	Økernlegene	Oslo
Norway	Rikshospitalet	Oslo
Norway	Betanien Hospital	Skien
Norway	Rosten legesenter	Tiller
Norway	Universitetssykehuset Nord-Norge HF	Tromsø
Norway	St.Olavs Hospital	Trondheim

Sponsors (1)

Lead Sponsor	Collaborator
Pfizer

Country where clinical trial is conducted

Norway, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in baseline of Patient Global Assessment of Pain Intensity (VAS) at week 12	Global Pain Intensity score (VAS): is a participant reported assessment of pain on a 0 to 100 millimeter (mm) Visual Analog Scale (VAS) where 0 mm= no pain and 100=most severe pain.	Baseline, Week 12	No
Secondary	Participants Global Assessment of Pain Intensity (VAS)	Global Pain Intensity score (VAS): is a participant reported assessment of pain on a 0 to 100 millimeter (mm) Visual Analog Scale (VAS) where 0 mm= no pain and 100=most severe pain.	Weeks 2, 6	No
Secondary	Bath Ankylosing Spondylitis Functional Index (BASFI)	BASFI is a validated self assessment tool that determines the degree of functional limitation in AS. Utilizing a VAS of 0-10 (0 = easy, 10 = impossible), participants answered 10 questions assessing their ability in completing normal daily activities or physically demanding activities. The BASFI score is a mean score of the 10 questions.	Weeks 2, 6	No
Secondary	Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)	BASDAI is a validated self assessment tool used to determine disease activity in participant with Ankylosing Spondylitis (AS). Utilizing a Visual Analog Scale (VAS) of 0-10 (0=none and 10=very severe) participant's answered 6 questions measuring discomfort, pain and fatigue. The final BASDAI score averages the individual assessments for a final score range of 0-10	Weeks 2, 6	No
Secondary	Participants and Physicians Global Assessment of Disease Activity	Participants are asked at each visit the following questions: Taking everything into account how do you assess the activity of your disease in the last 2 days on a scale where: 0=disease inactive with no symptoms and 100=disease extremely active?	Weeks 2, 6, 12	No
Secondary	Participants and Physicians Global Assessment of Treatment	The patients will be asked up to four global questions about safety and efficacy of the trial medication and about their current disease status. Responses are done on a 5 point scale where 0=no effect, 1=poor effect, 2=moderate effect, 3=good effect, and 4=excellent. At the same visits the investigator will be asked to do his/her own judgment of the efficacy and tolerance of the treatment (excellent, good, moderate, poor).	Week 12	No
Secondary	Participants Consumption of Rescue Medication	Participant consumption of rescue medication (paracetamol) calculated at each individual visit (except from the screening visit) by counting returned tablets versus tablets dispensed at the previous visit.	Baseline, Weeks 2, 6, 12	No